Axonics, Inc. announced that the U.S. Food and Drug Administration has approved the company's fourth-generation rechargeable sacral neuromodulation system. The newly approved Axonics R20™ neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to just once every 6 to 10 months for only one hour. This compares to the third-generation's recharge interval of once a month for one hour.

The Axonics R20 neurostimulator utilizes the same small 5cc form factor as the Axonics R15™ and is paired with the same tined lead and intuitive patient remote control. Axonics plans to commercially launch the product in the United States in March.